Bayer, PeptiDream Ink Global Drug Discovery Pact

Bayer and PeptiDream, a public Japanese biopharmaceutical company, have entered into a global drug discovery collaboration across multiple therapeutic areas and target classes.

Under the agreement, Bayer and PeptiDream will work to identify new compounds for difficult-to-address drug targets by using PeptiDream's proprietary Peptide Discovery Platform System (PDPS) technology. The aim of the collaboration is to discover novel lead structures in areas of high unmet medical need across Bayer's strategic research areas such as oncology or cardiology.

Finding new lead structures is one of the major challenges in drug discovery . PeptiDream has developed a novel peptidebased hit-finding technology which offers starting points for lead-discovery projects for difficult-to-address targets based on the great magnitude of the libraries. The multi-year collaboration will complement Bayer's internal lead discovery capabilities and represents a strategic extension of Bayer's in-house technology portfolio.

Under the terms of this agreement, PeptiDream will receive an up-front payment as well as success-based milestone payments. Bayer owns the rights to novel lead structures generated in the course of the collaboration and obtains a license under PeptiDream's PDPS technology to the extent necessary for human therapeutic use (excluding peptide-drug conjugates) of those novel structures. PeptiDream will also receive royalties on successfully commercialized drugs that result from a collaboration program.